Predictive Biosciences’ $25M Series C round to pay for clinical trials
Predictive Biosciences plans to use its now-completed $25 million Series C round to begin commercializing its biomarker-based bladder cancer test. Predictive Biosciences completed a $25 million Series C round, saying it plans to use the money to complete clinical trials for its CertNDx bladder cancer assay and ready it for market. The assay reduces the […]
